AstraZeneca PLC Ordinary Shares (AZN) Analyst Ratings & Price Targets

AstraZeneca PLC Ordinary Shares

AZN · NYSE

Analyst Consensus

Buy

12 analysts

$185

Current

—

Low

$215

Average

—

High

Average target implies +15.95% versus the current price.

Analyst Ratings Synthesis

The supplied consensus is Buy across 12 analysts, with a mean target of $215; the stated consensus feed provides no low or high target. Other supplied aggregators show mean targets from $206.66 to $209.90, while ChartMill reports $209.53 based on 34 analysts, indicating variation across datasets rather than a verified individual target range. The evidence does not name the most- or least-bullish analysts, nor does it provide dated target revisions from the past week, so revision direction and the target spread among individual analysts cannot be established. The substantive business debate evident in the supplied coverage is whether oncology growth and pipeline progress can offset generic pressure on mature medicines.

Rating Actions

1 firm captured

Firm	Analyst	Rating	Price Target	Upside	Date	Source
Wall Street Zen	—	Hold Lowered rating	—	—	Oct 13, 2026	Open the report this row came from

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

ARGUS RESEARCH

B OF A GLBL RES

BMO CAPITAL MKT

DEUTSCHE BK SEC

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MORGAN STANLEY

TD COWEN

UBS

ZACKS RESEARCH

Symbol: AZN
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: Europe
Exchange: NYSE

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.

Key Issues

Bullish view

Q3 oncology sales grew 17%, and the company reported growth across its major therapy areas. Continued demand for newer medicines could offset erosion in mature drugs.

Bearish view

Generic pressure on mature medicines is already identified as an offset to growth. The evidence does not quantify whether oncology gains will consistently outpace that pressure.

Analyst Consensus

See all

Buy

12 analysts

$185

Current

—

Low

$215

Average

—

High

Average target implies +15.95% versus the current price.

Earnings History

BeatMissNo estimate

AstraZeneca PLC Ordinary Shares

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers